Komori
Financial results presentation4883Modalis Therapeutics CorporationPharmaceuticals

(Revised Correction) Notice Concerning the Correction to the Presentation Materials for the Second Quarter Results for the Fiscal Year Ending December 2026

The balance sheet and income statement on pages 26–27 of the earnings presentation materials for the second quarter of the fiscal year ending December 2026 were replaced to reflect corrections to the earnings summary.

Worth reading
61In focus
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Mixed performance
Direction inferred from the company’s description.
Scale
—
Displayed only when the document provides numerical figures.
Wording
Definitive
How definitive the wording is.

What was corrected and how

A subsequent correction by the company to the contents of an already published filing.

Original disclosure10 August 2026

Earnings presentation materials for the second quarter of the fiscal year ending December 2026

Open the original document
4 daysThe pre-correction wording stayed published for this period (Calculated from the Original Disclosure Date Indicated in the Document)
This correction2026-08-14
Location of correction (where in the original document)

pp. 26–27: Financial position at the end of the second quarter of 2026 (balance sheet and income statement)

Reason for correction

Following partial corrections to the "(Corrections and Corrections to Numerical Data) Earnings Summary for the Second Quarter (Interim Period) of the Fiscal Year Ending December 2026 [Japanese GAAP] (Consolidated)," dated 13 August 2026

What was corrected and how
ItemDetails
Disclosure subject to correctionEarnings presentation materials for the second quarter of the fiscal year ending December 2026
Original disclosure date10 August 2026
Location of correctionpp. 26–27: Financial position at the end of the second quarter of 2026 (balance sheet and income statement)
Reason for correctionFollowing partial corrections to the "(Corrections and Corrections to Numerical Data) Earnings Summary for the Second Quarter (Interim Period) of the Fiscal Year Ending December 2026 [Japanese GAAP] (Consolidated)," dated 13 August 2026
Items this document does not state (2)
Details of correctionImpact on Business Performance

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

The related presentation materials were corrected following partial corrections made to the earnings summary for the second quarter of the fiscal year ending December 2026 dated 13 August 2026.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
(Revised Correction) Notice Concerning the Correction to the Presentation Materials for the Second Quarter Results for the Fiscal Year Ending December 2026 | Modalis Therapeutics Corporation (4883) timely disclosure | Komori